{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T14:44:32Z","timestamp":1774449872353,"version":"3.50.1"},"reference-count":77,"publisher":"Wiley","issue":"11P2","license":[{"start":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T00:00:00Z","timestamp":1326326400000},"content-version":"vor","delay-in-days":1167,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:p>Cetuximab and panitumumab, monoclonal antibodies used to target the epidermal growth factor receptor (EGFR), were recently approved by the United States Food and Drug Administration for use as single agents or in combination with other chemotherapy drugs in the treatment of metastatic colorectal cancer. The anti\u2010EGFR monoclonal antibodies, either as single agents or in combination with chemotherapy, have demonstrated clinical activity in this setting. When combined with standard cytotoxic chemotherapy or other targeted agents (e.g., bevacizumab, an anti\u2010vascular endothelial growth factor monoclonal antibody), anti\u2010EGFR monoclonal antibodies have been well tolerated and produced minimal toxicities. However, cetuximab and panitumumab appear to benefit only select patients. Predictive markers of efficacy, including EGFR overexpression, development of skin rash, and the absence of a K\u2010<jats:italic>ras<\/jats:italic> mutation, have been evaluated in clinical studies to identify patients likely to respond to anti\u2010EGFR monoclonal antibody therapy. This review discusses recent clinical studies of anti\u2010EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer, predictive markers of their efficacy, and common toxicities associated with their use.<\/jats:p>","DOI":"10.1592\/phco.28.11-supp.31s","type":"journal-article","created":{"date-parts":[[2008,11,3]],"date-time":"2008-11-03T13:53:21Z","timestamp":1225720401000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clinical Use of Anti\u2010Epidermal Growth Factor Receptor Monoclonal Antibodies in Metastatic Colorectal Cancer"],"prefix":"10.1002","volume":"28","author":[{"given":"Dina K.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,12]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-007-0228-3"},{"issue":"1","key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1177\/17246008070221s411","article-title":"The future of anti\u2010EGFR therapy","volume":"22","author":"D'Andrea MR","year":"2007","journal-title":"Int J Biol Markers"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm218"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i44.5877"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-577"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666150-00011"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210377"},{"key":"e_1_2_1_10_2","unstructured":"ImClone Systems Inc.Erbitux (cetuximab) package insert. Branchburg NJ. Distributed and marketed by Bristol\u2010Myers Squibb Company Princeton NJ;2007."},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2006-0049"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H492"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","unstructured":"Amgen Inc. Vectibix (panitumumab) package insert. Thousand Oaks CA;2006.","DOI":"10.3833\/pdr.v2006i78.424"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071834"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.1193"},{"issue":"18","key":"e_1_2_1_17_2","article-title":"Cetuximab in combination with irinotecan\/5\u2010fluorouracil (5\u2010FU)\/folinic acid (FA) (FOLFIRI) in second\u2010 and third\u2010line treatment of metastatic colorectal cancer (mCRC): safety and efficacy analysis [abstract]","volume":"24","author":"Smith DM","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl392"},{"issue":"18","key":"e_1_2_1_19_2","article-title":"Randomized phase III study of irinotecan and 5\u2010FU\/FA with or without cetuximab in the first\u2010line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial [abstract]","volume":"25","author":"Cutsem E.","year":"2007","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj084"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.04.029"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn058"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.2183"},{"issue":"18","key":"e_1_2_1_24_2","article-title":"Cetuximab plus 5\u2010FU\/FA\/oxaliplatin (FOLFOX\u20104) versus FOLFOX\u20104 in the first\u2010line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study [abstract]","volume":"25","author":"Bokemeyer C.","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18","key":"e_1_2_1_25_2","article-title":"Cetuximab (C), oxaliplatin (Ox) and fluoropyrimidine (Fp): toxicity during the first 12 weeks of treatment for the first 804 patients entered into the MRC COIN (CR10) trial [abstract]","volume":"25","author":"Maughan T.","year":"2007","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_26_2","unstructured":"HeinemannV. MoosmannN. Vehling\u2010KaiserU. et al.XELIRI plus cetuximab versus XELOX plus cetuximab for first\u2010line therapy of metastatic colorectal cancer (CRC): a randomized trial of the AIO CRC study group.Presented at the 2007 gastrointestinal cancers symposium Orlando FL January 1921 2007."},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","unstructured":"VenookA. NiedzwieckiD. HollisD. et al.Phase III study of irinotecan\/5FU\/LV (FOLFIRI) or oxaliplatin\/5FU\/LV (FOLFOX) \u00b1 cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALBG 80203 preliminary results.Presented at the 42nd annual meeting of the American Society of Clinical Oncology Atlanta GA June 26 2006.","DOI":"10.1200\/jco.2006.24.18_suppl.3509"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22915"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.182"},{"issue":"18","key":"e_1_2_1_30_2","article-title":"Panitumumab antitumor activity in patients with metastatic colorectal cancer (mCRC) expressing \u2265 10% epidermal growth factor receptor (EGFr) [abstract]","volume":"24","author":"Berlin J.","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.1620"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm399"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2007.n.011"},{"key":"e_1_2_1_34_2","unstructured":"DouillardJ. SienaS. CassidyJ. et al.Phase III study (PRIME\/20050203) of panitumumab with FOLFOX4 compared to FOLFOX4 alone in patients with previously untreated metastatic colorectal cancer (mCRC): preliminary safety data.Presented at the 2008 gastrointestinal cancers symposium Orlando FL January 2527 2008."},{"key":"e_1_2_1_35_2","unstructured":"TortoraG. CaputoR. BiancoR. et al.Novel anticancer drugs TLR9 agonists interfere with EGFR signaling and potently synergize with EGFR inhibitors and with bevacizumab in wild type and cetuximab\u2010resistant colon cancer xenografts.Presented at the 2007 gastrointestinal cancers symposium Orlando FL January 1921 2007."},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0949"},{"key":"e_1_2_1_37_2","unstructured":"HechtJR MitchellE. ChidiacT. et al.An updated analysis of safety and efficacy of oxaliplatin(Ox)\/bevacizumab (bev) +\/\u2010 panitumumab (pmab) for first\u2010line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized controlled trial (PACCE).Presented at the 2008 gastrointestinal cancers symposium Orlando FL January 2527 2008."},{"key":"e_1_2_1_38_2","unstructured":"HechtJR MitchellE. ChidiacT. et al.Interim results from PACCE: irinotecan (Iri)\/bevacizumab (bev) \u00b1 panitumumab (pmab) as first\u2010line treatment (tx) for metastatic colorectal cancer (mCRC).Presented at the 2008 gastrointestinal cancers symposium Orlando FL January 2527 2008."},{"key":"e_1_2_1_39_2","unstructured":"National Cancer Institute Clinical Trials PDQ.Phase III randomized study of cetuximab and\/or bevacizumab in combination with either oxaliplatin fluorouracil and leucovorin calcium (FOLFOX) or irinotecan hydrochloride fluorouracil and leucovorin calcium (FOLFIRI) in patients with previously untreated metastatic adenocarcinoma of the colon or rectum. Available fromhttp:www.cancer.govsearchViewClinicalTrials.aspxcdrid455161&versionhealthprofessional. Accessed February 28 2008."},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.8900"},{"key":"e_1_2_1_41_2","doi-asserted-by":"crossref","unstructured":"BendellJC UronisH. MorseM. et al.Initial results of a phase II study of oxaliplatin (OX) capecitabine (CAP) bevacizumab (BV) and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC).Presented at the 2008 gastrointestinal cancers symposium Orlando FL January 2527 2008.","DOI":"10.1200\/jco.2008.26.15_suppl.4063"},{"issue":"18","key":"e_1_2_1_42_2","article-title":"Response to the combination of cetuximab, bevacizumab and irinotecan (cetux\/bev\/iri) in patients (pts) previously treated with 3rd\u2010line panitumumab, following disease progression on oxaliplatin, irinotecan and a fluoropyrimidine [abstract]","volume":"25","author":"Tubb EE","year":"2007","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_43_2","unstructured":"National Cancer Institute Clinical Trials PDQ.Trial of cetuximab bevacizumab and 5\u2010FU\/leucovorin versus oxaliplatin bevacizumab and 5\u2010FU\/leucovorin in metastatic colorectal cancer. Available fromhttp:www.cancer.govsearchViewClinicalTrials.aspxcdrid45 5161&versionhealthprofessional. Accessed February 28 2008."},{"key":"e_1_2_1_44_2","unstructured":"National Cancer Institute Clinical Trials PDQ.Phase III randomized study of irinotecan hydrochloride\u2010based chemotherapy and cetuximab with versus without bevacizumab in patients with metastatic colorectal cancer that progressed on first\u2010line therapy. Available fromhttp:www.cancer.govsearchViewClinicalTrials.aspxcdrid551934&versionhealthprofessional. Accessed February 28 2008."},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm607"},{"issue":"18","key":"e_1_2_1_46_2","article-title":"Optimal dose of cetuximab (C) given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1 w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC) [abstract]","volume":"24","author":"Tabernero J.","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_47_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.15118","article-title":"Efficacy and safety of cetuximab (C) given with a simplified, every other week (q2w), schedule in patients (pts) with advanced colorectal cancer (aCRC): a multicenter, retrospective study [abstract]","volume":"26","author":"Bouchahda M.","year":"2008","journal-title":"J Clin Oncol"},{"issue":"16","key":"e_1_2_1_48_2","article-title":"Flexible dosing schedules of panitumumab (ABX\u2010EGF) in cancer patients [abstract]","volume":"23","author":"Arends R.","year":"2005","journal-title":"J Clin Oncol"},{"issue":"16","key":"e_1_2_1_49_2","article-title":"Updated results from a dose and schedule study of panitumumab (ABX\u2010EGF) monotherapy, in patients with advanced solid malignancies [abstract]","volume":"23","author":"Weiner LM","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1509"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.09.013"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2006.s.012"},{"issue":"14","key":"e_1_2_1_53_2","first-page":"21","article-title":"Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer","volume":"20","author":"Grothey A","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi279"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.NCC.0000281758.85704.9b"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2006.n.033"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.8.2.141"},{"key":"e_1_2_1_58_2","unstructured":"HechtJR MitchellEP BarandaJ. et al.Panitumumab efficacy in patients with metastatic colorectal cancer (mCRC) with low or undetectable levels of epidermal growth factor receptor (EGFr): final efficacy andKRASanalyses.Presented at the 2008 gastrointestinal cancers symposium Orlando FL January 2527 2008."},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200507143530218"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.037"},{"issue":"18","key":"e_1_2_1_61_2","article-title":"Panitumumab activity in metastatic colorectal cancer patients with low or negative tumor epidermal growth factor receptor levels: an updated analysis [abstract]","volume":"25","author":"Mitchell EP","year":"2007","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.7.4.503"},{"key":"e_1_2_1_63_2","article-title":"The presence and intensity of the cetuximab\u2010induced acne\u2010like rash predicts increased survival in studies across multiple malignancies [abstract]","volume":"22","author":"Saltz L.","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"16","key":"e_1_2_1_64_2","article-title":"Cetuximab in refractory metastatic colorectal cancer: analysis of efficacy and response by patients and disease variables [abstract]","volume":"23","author":"Mirtsching B.","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2008.n.007"},{"issue":"18","key":"e_1_2_1_66_2","article-title":"Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials [abstract]","volume":"25","author":"Berlin J.","year":"2007","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-5-345"},{"issue":"18","key":"e_1_2_1_68_2","article-title":"Phase I\/II study of cetuximab dose\u2010escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data [abstract]","volume":"25","author":"Tejpar S.","year":"2007","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.7116"},{"key":"e_1_2_1_70_2","article-title":"KRAS status and efficacy in the first\u2010line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience [abstract]","volume":"26","author":"Cutsem E.","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_71_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.4000","article-title":"KRAS status and efficacy of first\u2010line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience [abstract]","volume":"26","author":"Bokemeyer C.","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1080\/07357900701511847"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp048143"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta11120"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2006.18.5.532"},{"key":"e_1_2_1_76_2","doi-asserted-by":"crossref","unstructured":"LoweryF.KRASstatus predicts response to treatment for metastatic colorectal cancer. OncologySTAT (updated February 5 2008). Available fromhttp:www.oncologystat.comhomenewsKRAS_Status_Predicts_Response_to_Treatment_for_Metastatic_Colorectal_Cancer_US.html. AccessedFebruary 21 2008.","DOI":"10.1038\/ncponc1144"},{"key":"e_1_2_1_77_2","unstructured":"Bristol Meyers Squibb Destination Access Web site.Erbitux (cetuximab). (updated March 2008.)Available fromhttp:www.destinationaccess.comindex.aspxbmscontentpgerbitux. Accessed August 4 2008."},{"key":"e_1_2_1_78_2","unstructured":"Amgen Reimbursement Connection Web site.Vectibix (panitumumab). (updated 2006.)Available fromhttp:www.ext.amgen.comreimbursement_connectionvectibix.html. Accessed August 4 2008."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.28.11-supp.31S","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.28.11-supp.31S","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:32:13Z","timestamp":1761046333000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.28.11-supp.31S"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":77,"journal-issue":{"issue":"11P2","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1592\/phco.28.11-supp.31S"],"URL":"https:\/\/doi.org\/10.1592\/phco.28.11-supp.31s","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11]]},"assertion":[{"value":"2012-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}